Stockscreener 앱 받기
0.8631
5.26%
0.0431
전일 마감가:
$0.82
열려 있는:
$0.825
하루 거래량:
686.59K
Relative Volume:
0.96
시가총액:
$38.54M
수익:
-
순이익/손실:
$-35.58M
주가수익비율:
-0.3257
EPS:
-2.65
순현금흐름:
$-42.82M
1주 성능:
+21.39%
1개월 성능:
-11.93%
6개월 성능:
-43.95%
1년 성능:
-29.25%
1일 변동 폭
$0.825
$0.8712
1주일 범위
$0.71
$0.8712
52주 변동 폭
$0.6573
$3.02
Iterum Therapeutics Plc Stock (ITRM) Company Profile
명칭
Iterum Therapeutics Plc
전화
(872) 225-6077
주소
3 DUBLIN LANDINGS, DUBLIN 1
ITRM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.8631 | 36.62M | 0 | -35.58M | -42.82M | -2.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-05-28 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2021-03-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-06-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-01-21 | 다운그레이드 | Gabelli & Co | Buy → Sell |
| 2019-12-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-06-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Iterum Therapeutics Plc 주식(ITRM)의 최신 뉴스
Advanced analytics toolkit walkthrough for Iterum Therapeutics plcMarket Sentiment Summary & Breakout Confirmation Trade Signals - Newser
News impact scoring models applied to Iterum Therapeutics plcDay Trade & Technical Pattern Based Signals - Newser
Analyzing Iterum Therapeutics plc with multi timeframe charts2025 Price Targets & Entry Point Confirmation Alerts - Newser
Leading vs lagging indicators on Iterum Therapeutics plc performance2025 Fundamental Recap & Capital Protection Trading Alerts - Newser
Will Iterum Therapeutics plc continue its uptrend2025 Short Interest & Verified Technical Signals - Newser
What institutional flow reveals about Iterum Therapeutics plc2025 Winners & Losers & Real-Time Buy Signal Alerts - Newser
Iterum Therapeutics plc stock trend outlook and recovery path2025 Year in Review & Weekly Top Gainers Alerts - Newser
Using Bollinger Bands to evaluate Iterum Therapeutics plc2025 Retail Activity & Technical Buy Zone Confirmations - Newser
Is Iterum Therapeutics plc reversing from oversold territoryMarket Activity Report & Reliable Volume Spike Alerts - Newser
Iterum Therapeutics plc (NASDAQ:ITRM) Q2 2025 Earnings Call Transcript - MSN
Using data filters to optimize entry into Iterum Therapeutics plc2025 Top Decliners & Safe Capital Growth Tips - Newser
ITRM Reports Results - AOL.com
Using Ichimoku Cloud for Iterum Therapeutics plc technicalsTrade Volume Report & Scalable Portfolio Growth Methods - Newser
Chart based exit strategy for Iterum Therapeutics plc2025 Breakouts & Breakdowns & Real-Time Market Sentiment Alerts - Newser
Price momentum metrics for Iterum Therapeutics plc explainedJuly 2025 Market Mood & Risk Controlled Daily Trade Plans - Newser
What’s next for Iterum Therapeutics plc stock priceLow Risk Stock Trade Opportunity Analysis - Newser
Using economic indicators to assess Iterum Therapeutics plc potentialStock Market Watch with Smart Filters - Newser
Iterum therapeutics (ITRM) director Dunne buys $10,854 in shares - Investing.com
Iterum therapeutics (ITRM) director Dunne buys $10,854 in shares By Investing.com - Investing.com Australia
Iterum Therapeutics Director Dunne Buys 15,000 Shares at $0.72/Share on Aug 8. - AInvest
Real time pattern detection on Iterum Therapeutics plc stockSecure Buy Strategy Based on Risk Parameters - Newser
Why Iterum Therapeutics plc stock attracts strong analyst attentionLow Drawdown Picks with Weekly Updates - Newser
Developing predictive dashboards with Iterum Therapeutics plc dataFuture Growth Stock Forecasting Strategy - Newser
Will Iterum Therapeutics plc stock recover after recent dropReal Stock Picks With Setup Verification - Newser
Iterum Therapeutics (NASDAQ:ITRM) Downgraded by Wall Street Zen to “Sell” - Defense World
Iterum Therapeutics PLC (NASDAQ:ITRM) Short Interest Up 54.6% in July - Defense World
ITRM Reports Results - The Motley Fool
Iterum Therapeutics PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Iterum Therapeutics (ITRM) Financial Outlook for 2025 - GuruFocus
Iterum Therapeutics plc SEC 10-Q Report - TradingView
Iterum Therapeutics reports Q2 results, launches ORLYNVAH, extends cash runway to 2026. - AInvest
Iterum Therapeutics to Launch ORLYNVAH™ for Uncomplicated UTIs in August 2025, Reports Q2 Financial Results - Quiver Quantitative
Iterum Therapeutics Reports Second Quarter 2025 Financial Results - The Manila Times
Iterum Therapeutics reports Q2 revenue, cash runway into 2026, ORLYNVAH launch in August. - AInvest
Iterum Earnings Show $13M Cash as Revolutionary UTI Antibiotic ORLYNVAH Readies for Historic Launch - Stock Titan
Iterum Therapeutics (NASDAQ:ITRM) Shares Down 2.5% – Here’s Why - Defense World
Iterum Therapeutics Plc (ITRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.88%
자본화:
|
볼륨(24시간):